Not admitted · Not a forecast
Rules 1.1.0 · as of 14 Sep 2026
Owen Scott Muir · Said 3 Sep 2026 · owen-2395
Quote
Not a forecast
“somebody has to do a large enough trial, submitted to the FDA, to change the label, and that just starts the conversation with payers about coverage.”
Continuation of the SNT-in-bipolar-depression point: the author says an FDA label change for accelerated TMS in bipolar depression requires a sufficiently large trial submitted to the FDA, and that a label change only begins the payer coverage conversation, so coverage will lag any label.
Descriptive, retrospective, or a statement of preference; no future state asserted.